ID17243A - Metode pembuatan komplek obat - Google Patents

Metode pembuatan komplek obat

Info

Publication number
ID17243A
ID17243A IDP971929A ID971929A ID17243A ID 17243 A ID17243 A ID 17243A ID P971929 A IDP971929 A ID P971929A ID 971929 A ID971929 A ID 971929A ID 17243 A ID17243 A ID 17243A
Authority
ID
Indonesia
Prior art keywords
spacer
drug compound
bound
carboxyl groups
polysaccharide derivative
Prior art date
Application number
IDP971929A
Other languages
English (en)
Indonesian (id)
Inventor
Kazuhiro Inoue
Hiroshi Susaki
Masahiro Ikeda
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of ID17243A publication Critical patent/ID17243A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IDP971929A 1996-06-06 1997-06-05 Metode pembuatan komplek obat ID17243A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14452296 1996-06-06

Publications (1)

Publication Number Publication Date
ID17243A true ID17243A (id) 1997-12-11

Family

ID=15364300

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP971929A ID17243A (id) 1996-06-06 1997-06-05 Metode pembuatan komplek obat

Country Status (16)

Country Link
US (1) US6291671B1 (de)
EP (1) EP0955064B1 (de)
JP (1) JP4137184B2 (de)
CN (1) CN1227034C (de)
AT (1) ATE273716T1 (de)
AU (1) AU723442B2 (de)
CA (1) CA2257233A1 (de)
DE (1) DE69730352T2 (de)
DK (1) DK0955064T3 (de)
EA (1) EA001897B1 (de)
ES (1) ES2229355T3 (de)
ID (1) ID17243A (de)
NO (1) NO323626B1 (de)
PT (1) PT955064E (de)
TW (1) TW409058B (de)
WO (1) WO1997046261A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
HK1040052B (zh) * 1998-05-22 2006-09-15 第一制药株式会社 药物复合物
BR0112287A (pt) * 2000-06-29 2003-05-06 Daiichi Seiyaku Co Composto dds e seu método de preparação
CA2445985A1 (en) * 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US7691830B2 (en) * 2005-02-17 2010-04-06 Clive Elson Method and composition for treatment of a mucosal tissue disorder
WO2006121803A1 (en) 2005-05-05 2006-11-16 Sensient Flavors Inc. Production of beta-glucans and mannans
US8354392B2 (en) 2005-07-06 2013-01-15 Seikagaku Corporation Drug-introduced photo-crosslinked hyaluronic acid derived gel
ITPD20050242A1 (it) 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
CA2828605C (en) 2010-05-25 2019-01-15 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
RS60000B1 (sr) 2012-10-11 2020-04-30 Daiichi Sankyo Co Ltd Veznici za antitelo-lek konjugate
EP2910573B1 (de) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Durch bindung über einen linker mit hydrophiler struktur hergestelltes antikörper-wirkstoff-konjugat
MX371095B (es) 2013-04-10 2020-01-16 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
SMT202500227T1 (it) 2013-12-25 2025-09-12 Daiichi Sankyo Co Ltd Metodo per produrre un coniugato anticorpo anti-trop2-farmaco
HRP20241783T1 (hr) 2014-01-31 2025-02-28 Daiichi Sankyo Company, Limited Anti-her2 antitijelo-lijek konjugat
CN111228511B (zh) 2014-04-10 2024-06-18 第一三共株式会社 抗her3抗体-药物偶联物
EP3130608B1 (de) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2-antikörper)-arzneimittelkonjugat
JP6787890B2 (ja) 2015-06-29 2020-11-18 第一三共株式会社 抗体−薬物コンジュゲートの選択的製造方法
EP3386956B1 (de) 2015-12-10 2021-07-14 Syndevrx, Inc. Fumagillolderivate und polymorphe davon
AU2017206718B2 (en) 2016-01-11 2021-09-30 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
TWI862473B (zh) 2016-12-12 2024-11-21 日商第一三共股份有限公司 抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
TWI780104B (zh) 2017-01-17 2022-10-11 日商第一三共股份有限公司 抗gpr20抗體及抗gpr20抗體-藥物結合物、以及其製造方法及用途
TWI855528B (zh) 2017-05-15 2024-09-11 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
SMT202300227T1 (it) 2018-05-18 2023-09-06 Glycotope Gmbh Anticorpo anti-muc1
IL280296B2 (en) 2018-07-27 2025-03-01 Daiichi Sankyo Co Ltd Drug recognition protein of an antibody-drug conjugate
AU2019315177A1 (en) 2018-07-31 2021-02-25 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
CA3117666A1 (en) 2018-10-26 2020-04-30 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
PE20220563A1 (es) 2019-07-10 2022-04-13 Cybrexa 2 Inc Conjugados peptidicos de citotoxinas como terapeuticos
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
MX2024000612A (es) 2021-07-19 2024-03-14 Zeno Man Inc Inmunoconjugados y metodos.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746920A (en) * 1980-09-03 1982-03-17 Kyosei Seiyaku Kk Drug for digestive tract
DE3152319C2 (de) 1980-09-03 1986-05-07 Kyosei Pharmaceutical Co., Ltd., Hokkaido Verwendung einer Lösung eines Salzes der Alginsäure zur Behandlung von Strahlenschäden und Ulcera
JPS59220197A (ja) * 1983-05-30 1984-12-11 Snow Brand Milk Prod Co Ltd 新規な含窒素多糖体およびその製造方法
JP2604930B2 (ja) 1990-12-14 1997-04-30 株式会社ディ・ディ・エス研究所 ヒアルロン酸およびコンドロイチン誘導体
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
WO1992014759A1 (fr) 1991-02-21 1992-09-03 Drug Delivery System Institute, Ltd. Carboxymethylmannoglucane et derive
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
PT640622E (pt) 1993-02-26 2000-11-30 Drug Delivery System Inst Ltd Derivados de polissacaridos e veiculos para farmacos
JPH0784481A (ja) 1993-06-26 1995-03-31 Ricoh Co Ltd 画像形成装置
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts

Also Published As

Publication number Publication date
DE69730352D1 (de) 2004-09-23
WO1997046261A1 (fr) 1997-12-11
EP0955064A4 (de) 2000-12-06
EA001897B1 (ru) 2001-10-22
NO323626B1 (no) 2007-06-18
AU723442B2 (en) 2000-08-24
AU2978897A (en) 1998-01-05
NO985667D0 (no) 1998-12-04
EP0955064A1 (de) 1999-11-10
US6291671B1 (en) 2001-09-18
NO985667L (no) 1999-02-04
CA2257233A1 (en) 1997-12-11
ATE273716T1 (de) 2004-09-15
CN1227034C (zh) 2005-11-16
ES2229355T3 (es) 2005-04-16
DK0955064T3 (da) 2004-12-06
JP4137184B2 (ja) 2008-08-20
EP0955064B1 (de) 2004-08-18
EA199900002A1 (ru) 1999-08-26
TW409058B (en) 2000-10-21
PT955064E (pt) 2004-10-29
DE69730352T2 (de) 2005-09-08
CN1227500A (zh) 1999-09-01

Similar Documents

Publication Publication Date Title
ID17243A (id) Metode pembuatan komplek obat
FI893467L (fi) Menetelmä lääkeaineena käyttökelpoisten 4-oksokinoliini-3-karboksyylihapon johdannaisten valmistamiseksi
FI885623A7 (fi) Menetelmä lääkeaineina käyttökelpoisten substituoitujen propaani-fosfiinihappoyhdisteiden valmistamiseksi
NO177004C (no) Analogifremgangsmåte for fremstilling av 7-substituerte derivater av 3,5-dihydroksyhept-6-ynsyre
DE69900462D1 (de) Konjugate von dns und pns und verfahren zu deren herstellung
CA2399187A1 (en) Kahalalide compounds
FI881496A7 (fi) Menetelmä aminohappojen valmistamiseksi tai uuttamiseksi lannasta
NO932232D0 (no) Organiske cerium (iv)-forbindelser, deres fremstilling oganvendelse
BG50164A3 (en) Method for preparing of amicacine
FI861655L (fi) Menetelmä lääkeaineina käyttökelpoisten griseoliinihapon johdannaisten valmistamiseksi
MY131384A (en) Novel 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
EP1336603A4 (de) Verfahren zur einführung von aminogruppen und verfahren zur synthese von aminosäuren
ES542956A0 (es) Un procedimiento para preparar un derivado de oxazolina
SE8502315D0 (sv) Improved transamination process for producing amino acids
PT83837A (de) Verfahren zur herstellung von peptiden unter der verwendung von perchloraten
RU93031156A (ru) Способ получения плазмид, кодирующих химерный белок с последовательностью соматостатина, штамм бактерий escherichia coli - продуцент этого белка, белок, полученный в этом штамме, содержащий фрагмент ацетилтрансферазы, спейсер и иммуногенный соматостатин
AU629008B2 (en) Compounds from biopolymrs and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof
FI885638A0 (fi) Menetelmä lääkeaineina käyttökelpoisten griseoliinihappomonoesterijohdannaisten valmistamiseksi
EP0226132A3 (de) Dipeptide mit C-terminalem Phosphinothricin, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
GR3002989T3 (en) Process for the production of n-acylated mercapto-alpha-amino acids
ATE92483T1 (de) Verfahren zur herstellung von thiophenderivaten sowie dihydrothiophen-1-oxide.
CY1106051T1 (el) ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ Ν-ΠΡΟΣΤΑΤΕΥΜΕΝΩΝ ΑΖΕΤΙΔΙΝΟ-2-ΚΑΡΒΟΞΥΛΙΚΩΝ ΟΞΕΩΝ (AzeOHs)
FI884177A7 (fi) Menetelmä L-aminohappojen valmistamiseksi.
FI871761A7 (fi) Menetelmä L-aminohappojen valmistamiseksi transaminaation avulla.
AT387380B (de) Verfahren und zwischenprodukte fuer n-(s-3alkyl-heptanoyl)-d-gamma-glutamyl-glycyl-dalanin